Natalie Holles, Third Harmonic Bio CEO

First of more? Third Har­mon­ic prices up­sized IPO to raise $185M

Third Har­mon­ic Bio pulled it off.

The At­las-found­ed biotech, which came out of stealth just ear­li­er this year with for­mer Au­dentes CEO Na­tal­ie Holles at the helm, has priced an IPO that will bring in $185.3 mil­lion be­fore tak­ing com­mis­sions, dis­counts and oth­er fees in­to ac­count.

Giv­en the chilly pub­lic mar­ket, it is per­haps un­usu­al that Third Har­mon­ic is mak­ing the jump to Nas­daq at all. No­tably, while it priced in the mid­dle of the pro­posed range — $17 per share — the com­pa­ny is boast­ing of an up­sized of­fer­ing. It end­ed up sell­ing more than 10 mil­lion shares rather than the 9 mil­lion orig­i­nal­ly planned.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA